Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Auditor change
Viridian Therapeutics, Inc. (MGEN) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/09/2023 8-K Quarterly results
Docs: "Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update"
03/08/2023 8-K Quarterly results
Docs: "Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates"
08/15/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/10/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"VIRIDIAN THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES"
11/04/2021 8-K Quarterly results
Docs: "VIRIDIAN THERAPEUTICS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES"
05/06/2021 8-K Quarterly results
03/25/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "MIRAGEN REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES"
08/05/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
03/11/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "MIRAGEN REPORTS THIRD QUARTER 2019 RESULTS AND PROVIDES CORPORATE UPDATE"
08/07/2019 8-K Quarterly results
05/08/2019 8-K Quarterly results
Docs: "MIRAGEN ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE"
11/07/2018 8-K Quarterly results
Docs: "MIRAGEN THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE"
08/07/2018 8-K Quarterly results
Docs: "MIRAGEN THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE"
05/09/2018 8-K Quarterly results
Docs: "FORM 8-K",
"MIRAGEN THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE"
11/08/2017 8-K Quarterly results
Docs: "Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934 . Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected...",
"MIRAGEN THERAPEUTICS REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE"
08/11/2017 8-K Quarterly results
Docs: "MIRAGEN THERAPEUTICS REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE"
05/10/2017 8-K Quarterly results
Docs: "Miragen Therapeutics, Inc. Condensed Consolidated Statements of Operations Three Months Ended March 31, 2017 2016 Revenue: Revenue under strategic alliance and collaboration $ 10 $ 917 Grant revenue 452 — Total revenue 462 917 Operating expenses: Research and development 4,120 3,466 General and administrative 3,281 992 Total operating expenses 7,401 4,458 Loss from operations Other income : Interest and other income 30 7 Interest and other related expense Net loss Accretion of redeemable convertible preferred stock to redemption value Net loss available to common stockholders $ $ Net loss per share, basic and diluted $ $ Weighted-average shares used to compute basic and diluted net loss per share 11,555,286 651,041 Miragen Therapeutics, Inc. Selected Financial Information Condensed Co..."
05/16/2016 8-K Quarterly results
Docs: "Signal Genetics Highlights Recent Achievements and Reports First Quarter 2016 Financial Results Record Volume and Net Revenue from MyPRS® Sold to Clinical Customers CARLSBAD, Calif., May 16, 2016 -- Signal Genetics, Inc. , a commercial stage, molecular genetics diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today reported recent achievements and financial results for the first quarter ended March 31, 2016. Recent Highlights Record net revenue from clinical customers increased 244% in the first quarter of 2016 over first quarter of 2015 Record number of tests billed for clinical customers was 93% higher in the first quarter of 2016 compared to the first qu..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy